Skip to content

Staged Extended Thoracoscopic Sympathicotomy for Palmo-axillo-plantar Hyperhidrosis

Staged Extended Thoracoscopic Sympathicotomy for Palmo-axillo-plantar Hyperhidrosis; a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02728297
Enrollment
42
Registered
2016-04-05
Start date
2010-01-31
Completion date
2016-03-31
Last updated
2016-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperhidrosis

Brief summary

Evaluation of staged endoscopic thoracoscopic sympathicotomy in treatment of palmo-axillo-plantar hyperhidrosis

Detailed description

This is a pilot study that investigates the efficacy of video-assisted endoscopic sympathicotomy from the level of T3 to T12 on combined palmar and plantar hyperhidrosis. Ablation of ascending sympathetic fibers would help alleviating both types of hyperhidrosis in a single setting.

Interventions

PROCEDUREStaged ETS

Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients with combined palmo-axillo-plantar hyperhidrosis of ASA grade I and II

Exclusion criteria

* Patients under 16 years. * Patients with bradycardia (heart rate \<80 beats per minute). * Patients with concomitant lung pathology, frozen mediastinum, pleural effusion, or history of intercostal tube insertion. * Patients with cardiac problems with ejection fraction less than 60%. * Patient suffering from isolated palmo-axillary hyperhidrosis not associated with plantar hyperhidrosis. * Patients suffering from craniofacial hyperhidrosis, either isolated or combined with other areas of hyperhidrosis.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in severity of hyperhidrosis on visual analogue scale at 24 months24 monthsdecrease in the severity of hyperhidrosis, both palmar and plantar, according to visual analogue scale

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026